Strategic Partner(s)

Sam Hoare: Receptor Residence Time and GPCR Data Analysis

For most of GPCR pharmacology's history, affinity was the number that drove decisions. Which ligand binds tightest, ranks highest, earns the most attention in an SAR campaign. But affinity is a snapshot. It tells you how tightly a compound binds at equilibrium — not how long it stays.

When Sam Hoare and the CRF receptor team at Neurocrin Biosciences discovered that their lead compound sat on the receptor for seven hours while a failed backup fell off in fifteen minutes, it exposed a variable drug discovery had been systematically ignoring. That discovery became the foundation of a career built on the data most pharmacologists generate but don't analyze.

Sam Hoare brings a data analyst's perspective to GPCR pharmacology — one trained in allosteric modulation, sharpened in Class B receptor biology at the NIH, and refined across fifteen years of industrial drug discovery. His current work extends that logic into signaling kinetics: the time dimension in GPCR signaling that labs routinely measure and almost never formally quantify. For Hoare, the unsolved problem isn't the biology — it's the math no one wrote down.

About the Guest

Sam Hoare is the founder of Pharmechanics, a pharmacology data analysis consultancy. After a PhD on allosteric modulation of dopamine receptors in Philip Strange's UK lab and a postdoc at the National Institutes of Health studying Class B GPCRs, he spent fifteen years at Neurocrin Biosciences working on CRF receptor drug discovery programs that advanced compounds into clinical trials. Hoare now consults for biotech and pharmaceutical clients on GPCR data analysis, receptor binding kinetics, and pharmacological modeling. His independent research focuses on developing accessible mathematical tools for kinetic analysis of GPCR signaling data, including freely available Prism templates and Excel simulators.

Scientific Themes of the Conversation

Receptor residence time as a determinant of in vivo drug efficacy — and why affinity alone is insufficient
Signaling kinetics: quantifying the time dimension of GPCR pharmacology
Allosteric modulation and the mathematical foundations of receptor theory
Biased agonism and constitutive activity as practical tools in the drug discovery toolbox
The tractability of GPCRs as a pharmacological system — assay accessibility, theory, and the generous culture of the field
Scientific consulting: translating deep pharmacological expertise into independent problem-solving practice

Key Insights from the Conversation

1. The Off-Rate That Saved a Program

Standard binding assays showed identical affinity. But when Beth Fleck measured dissociation rates of the CRF receptor radioligands, the compound that worked in vivo stayed on the receptor for seven hours at room temperature. The failed backup fell off in fifteen minutes. The Neurocrin team had to confront an explanation no assay had been designed to find — and then built new SAR campaigns around it.

2. Affinity Is a Snapshot; Time Is the Story

Hoare draws a sharp analogy: running pharmacology dose-response experiments for decades without fitting a sigmoid curve to calculate EC50 would be considered absurd. Yet that is precisely how most labs treat time-course signaling data — collecting it, plotting it, and moving on without extracting a quantitative parameter. His ongoing research exists to close that gap.

3. GPCR Theory Was Built to Be Used

One of Hoare's recurring arguments is that GPCRs are unusually tractable — not just as biological targets, but as analytical systems. The underlying pharmacological theory, from operational models of agonism to allosteric binding equations, was designed to be applied by bench scientists. The barrier is not the math itself but the habit of reaching for it.

4. A Mentor Who Worked at the Bench

During a difficult stretch of his NIH postdoc, Hoare's supervisor Ted Usdin handed him a defined molecular biology project and spent two months working alongside him at the bench. The intervention was straightforward. The effect on Hoare's confidence — and ultimately his career — was not. He describes it as one of the moments his career most depended on.

5. The Variable Most Drug Programs Miss

The CRF residence time story is not unique in Hoare's telling. Across multiple programs — including work on a vesicular transporter where in vitro affinity at pH 7.4 vanished entirely at the physiological vesicle pH of 5.5 — the pattern recurs: assays designed for convenience rather than physiological relevance produce data that can't predict what happens in vivo. The pharmacologist's job is to identify which variable is missing.

6. Emotional Intelligence as a Consultant's Core Skill

Hoare was not expecting consulting to teach him about emotional intelligence. What he found was that clients arriving with a data problem are rarely arriving with just a data problem. The ability to serve as a sounding board — to help people relax around their data and see what was obscured by the pressure of having it not make sense — turned out to be as important as the pharmacological expertise he was hired for.

7. Early-Career Researchers Know More Than They Think

Hoare makes an argument that surprised him when he first articulated it: a newly minted PhD who has spent six years on a single GPCR target knows things a company working on that receptor genuinely cannot find anywhere else. The practical knowledge of what buffer conditions work, what assay artifacts to expect, what the literature actually shows — that depth of expertise is marketable, and most early-career scientists don't recognize that they have it.

Episode Timeline

Timestamps are AI-generated from the transcript and may not reflect final edited video timing.

00:00 Sponsor message

00:35 Introducing Sam Hoare: pharmacology data analyst and GPCR consultant

03:19 Origin story — the ATP calculation that first connected math to biology

06:16 PhD with Philip Strange: allosteric modulation of dopamine receptors and the first aha moment

16:53 Why GPCRs? Tractability, accessible theory, and a famously generous field

22:55 NIH postdoc: Class B GPCRs, mentorship, and conversations with Nobel laureates

35:38 Into industry: the CRF receptor team at Neurocrin Biosciences

43:25 The off-rate aha moment: seven hours on the receptor versus fifteen minutes

52:22 Founding PharmaChanics: the decision to leave industry and go independent

01:16:46 Signaling kinetics: the time dimension most pharmacologists skip

01:45:04 Biased agonism and residence time as tools in the drug discovery toolbox

01:52:09 Building a consulting practice: network, marketing, and knowing your worth

02:05:22 Top three aha moments from a career in pharmacological data analysis

Selected Quotes

"The one that works had a really long residence time on the receptor. We measured it at room temperature and it didn't come off after seven hours. There was just no dissociation. And the one that didn't work in vivo came off in fifteen minutes."

"Imagine doing pharmacology dose-response experiments for twenty years without applying the sigmoid curve fit to determine the EC50. To me, that's what we've been doing with time-course signaling data."

"He basically gave me a cookie-cutter molecular biology project and worked with me at the bench directly for two months. It completely restored my confidence. I kind of owe a lot of my career to Ted."

"My talent really is in data analysis. People would always come to me for that rather than for doing the experiments — and one of the reasons I set up my consultancy was that biology was becoming so technical that it was like I decided to specialize."

About Dr. Samuel Hoare

Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors, from the University of Kent, United Kingdom. He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class B GPCRs as part of his postdoctoral training.

Today, Sam is a pharmacology data analyst and the founder of Pharmechanics LLC, a consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics and the understanding of receptor systems. As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics, particularly GPCR antagonists.

Before founding Pharmechanics in 2016, Dr. Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences. He guided the in vitro biology efforts of the company for numerous drug discovery campaigns. Sam is known for demystifying complicated and newly-emerging pharmacology concepts, enabling them to be applied by project teams in optimizing new molecules.

I very much enjoyed chatting with Sam about his love for GPCRs, kinetics, and decorticate the complexities of GPCR function to better target receptors.

Dr. Samuel Hoare on the web